Completed

A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

radiation therapy

+ radiation therapy

Radiation
Who is being recruted

Neoplasms+5

+ Neoplastic Processes

+ Neurologic Manifestations

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2004
See protocol details

Summary

Principal SponsorNCIC Clinical Trials Group
Last updated: August 21, 2023
Sourced from a government-validated database.Claim as a partner

Study start date: January 22, 2004

Actual date on which the first participant was enrolled.

OBJECTIVES: Primary Compare pain relief in patients undergoing single-fraction vs multiple-fraction re-irradiation of painful bone metastases at 2 months after treatment. Secondary Compare overall pain relief in patients treated with these regimens. Compare time to pain progression in patients treated with these regimens. Assess relationship between response to initial radiation and pain relief after re-irradiation in these patients. Compare changes in functional interference after re-irradiation using the Brief Pain Inventory in patients treated with these regimens. Compare quality of life of patients treated with these regimens (patients in Canada, France, the Netherlands, and patients registered through RTOG). Determine characteristics of non-responders (to both initial and re-irradiation) among patients treated with these regimens. Monitor the incidence of acute severe radiation-related side effects in patients treated with these regimens. Monitor the incidence of in-field pathological fractures and spinal cord compression in patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to response to initial radiotherapy (yes vs no), initial fractionation (single fraction vs multiple fraction), and participating center. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive single-fraction radiotherapy (8Gy) on day 1. Arm II: Patients receive multiple-fraction radiotherapy (to a total of 20Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions. At least 4 weeks after the first re-treatment, patients in both arms may receive a second re-treatment at the discretion of the treating oncologist. Patients complete a Brief Pain Inventory questionnaire at baseline, on days 7 and 14, monthly during months 1-6, and at months 9 and 12. Acute Toxicities are assessed on days 7 and 14. Quality of Life is assessed at baseline and then monthly during months 1-6 for patients from participating groups. Patients are followed for up to 1 year. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 850 patients will be accrued for this study.

NCT00080912NCT00797173
Principal SponsorNCIC Clinical Trials Group
Last updated: August 21, 2023
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

850 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

NeoplasmsNeoplastic ProcessesNeurologic ManifestationsPathologic ProcessesSigns and SymptomsPathological Conditions, Signs and SymptomsNeoplasm MetastasisPain

Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed malignancy Diagnosis by needle biopsy, bone marrow biopsy, cytology, or surgical biopsy or resection Bone metastases at clinically painful areas confirmed by any of the following: Plain radiographs Radionuclide bone scans CT scans Magnetic resonance imaging Worst pain score of ≥ 2/10 using the baseline Brief Pain Inventory Pain arising from previously irradiated metastases and not from progressive disease in adjoining or remote areas Initial radiotherapy field is reproducible for re-irradiation Current treatment field for palliative radiotherapy must be the same size or smaller than the initial treatment field No clinical or radiological evidence of pathological fractures in the target site extremities. No radiological evidence of high-risk lesions for pathological fractures in the extremities (lytic lesions > 3cm or > 50% cortical erosion of bone diameter) if target site AND patient is a candidate for surgical intervention. No clinical or radiological evidence of spinal cord compression at target site. PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 50-100% Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other Not pregnant or nursing Fertile patients must use effective barrier contraception Able and willing to complete quality of life questionnaire in English, French, Dutch, or Spanish (if randomized by Canadian, Dutch, French or RTOG centre) Must be accessible for treatment follow-up Informed consent PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy See Disease Characteristics No more than 1 prior course of radiotherapy to the target site No prior radiotherapy dose ≥ 24 Gy in 6 fractions, 27 Gy in 8 fractions, or 30 Gy in 10 fractions to the spine or any part of the pelvis encompassing small or large bowel and/or the rectum, if these sites are being treated on study Initial doses of 24 Gy in 6 fractions, 27 Gy in 8 fractions or 30 Gy in 10 fractions to the acetabulum or hip and proximal femur allowed as long as the medial field border of the initial treatment did not cross midline No prior radiotherapy dose > 30Gy in 10 fractions to the ribs or extremities if these sites are being treated on study More than 30 days since prior strontium chloride Sr 89 More than 30 days since prior half-body radiotherapy, including the current re-irradiation field At least 4 weeks since initial radiotherapy Surgery No prior palliative surgery in treatment area No concurrent surgical intervention on treatment area Other No prior participation on this protocol No plan to make an immediate change in analgesic regimen

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients receive single-fraction radiotherapy (8 Gy) on day 1.

Group II

Active Comparator
Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Tom Baker Cancer Centre

Calgary, CanadaOpen Tom Baker Cancer Centre in Google Maps

The Vitalite Health Network - Dr. Leon Richard

Moncton, Canada

Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Canada

Cancer Centre of Southeastern Ontario at Kingston

Kingston, Canada
Completed12 Study Centers